ERYTECH Pharma’s sickle cell treatment receives positive opinion for Orphan Drug Designation from the European Medicines Agency

Erytech Pharma announces that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) adopted a positive opinion to grant Orphan Drug Designation (ODD) to its investigational product ENHOXY® for sickle cell disease.

Menu